Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP raised its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 94.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 199,460 shares of the biopharmaceutical company's stock after buying an additional 97,017 shares during the period. Two Sigma Investments LP owned about 0.34% of Vanda Pharmaceuticals worth $955,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of VNDA. Quantinno Capital Management LP purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $48,000. XTX Topco Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $69,000. Zacks Investment Management acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at about $74,000. ProShare Advisors LLC lifted its stake in shares of Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 4,599 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Vanda Pharmaceuticals by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 3,370 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock traded up $0.07 during trading on Tuesday, hitting $4.66. 375,208 shares of the stock traded hands, compared to its average volume of 660,211. The firm has a market capitalization of $274.63 million, a P/E ratio of -14.56 and a beta of 0.66. The firm's fifty day moving average price is $4.30 and its 200-day moving average price is $4.56. Vanda Pharmaceuticals Inc. has a 52-week low of $3.81 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. As a group, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were purchased at an average cost of $4.40 per share, for a total transaction of $44,000.00. Following the acquisition, the chief executive officer now owns 2,325,731 shares in the company, valued at $10,233,216.40. The trade was a 0.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.00% of the company's stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.